The Challenge

A specialty pharma company was preparing for pivotal reimbursement negotiations for a high-cost oncology therapy.
Their initial value proposition focused heavily on clinical efficacy but failed to:

​

• Quantify system-wide cost savings (e.g., reduced hospitalizations, fewer ICU stays)
   

• Include patient-centric outcomes like quality-of-life improvements
   

• Address budget impact concerns up front
   

Payers perceived the product as “promising, but expensive,” creating a risk of restricted reimbursement or prolonged negotiations.

 

Our Approach
We rebuilt the value proposition to make it payer-centric and persuasive:

​

🔹 Unmet Need Framing
Presented disease burden, late-stage treatment costs, and real-world survival gaps — framing urgency.

​

🔹 Differentiation Narrative
Used indirect treatment comparisons (ITC/NMA) to highlight superiority over standard of care.

​

🔹 Economic Storytelling
Linked clinical outcomes to avoided admissions, reduced resource use, and modeled 3-year budget impact.

​

🔹 Patient and Caregiver Voice
Incorporated validated HRQoL and caregiver burden data to humanize the impact.

​

🔹 Transparency & Post-Launch Plan
Included sensitivity analyses and a clear plan for RWE collection to reassure payers about long-term evidence.

 

The Results

✔️ Positive Payer Feedback – Negotiations focused on access pathways, not on price objections.

✔️ Faster Time-to-Listing – Achieved national reimbursement 3 months earlier than expected.

✔️ Broader Access – Product was reimbursed with minimal restrictions compared to competitors.

✔️ Internal Adoption – The revised value proposition became the foundation for affiliate payer decks and GVD updates.

 

The Insight
A value proposition isn’t just what you say — it’s what payers hear.

​

👉 Lesson Learned: The most effective value propositions speak to payer pain points, show system-level impact, and build trust through transparency. When you shift from “our data” to “your decision,” access outcomes improve.